{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "medicine:vascular:pharmacology:antiplatelet:ap-001",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T03:56:00.000Z",
    "contributors": ["copilot"],
    "confidence": 0.95,
    "status": "validated",
    "board_yield": "HIGH"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology/antiplatelet",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "foundational"
  },
  "content": {
    "title": "Antiplatelet Therapy in Vascular Disease",
    "definition": "Pharmacological inhibition of platelet aggregation to prevent arterial thrombosis in atherosclerotic vascular disease. Cornerstone of secondary prevention in peripheral arterial disease, coronary artery disease, and cerebrovascular disease.",
    "key_concepts": [
      {
        "term": "Aspirin",
        "description": "Irreversibly inhibits cyclooxygenase-1 (COX-1) → blocks thromboxane A2 synthesis → inhibits platelet aggregation. Effect lasts platelet lifespan (7-10 days). Dose: 75-325mg daily for vascular disease"
      },
      {
        "term": "Clopidogrel (Plavix)",
        "description": "P2Y12 ADP receptor antagonist; prodrug requiring CYP2C19 metabolism; irreversible inhibition. Alternative to aspirin or combined with aspirin (DAPT). Dose: 75mg daily"
      },
      {
        "term": "Dual Antiplatelet Therapy (DAPT)",
        "description": "Aspirin + P2Y12 inhibitor; indicated after coronary/peripheral stenting; typical duration 1-12 months depending on stent type and bleeding risk; increases bleeding but reduces thrombotic events"
      },
      {
        "term": "Ticagrelor",
        "description": "Direct-acting reversible P2Y12 inhibitor; faster onset than clopidogrel; not a prodrug (no CYP2C19 dependence). Dose: 90mg BID (or 60mg BID for PAD). Side effects: dyspnea, bradycardia"
      },
      {
        "term": "Prasugrel",
        "description": "Potent irreversible P2Y12 inhibitor; faster, more predictable than clopidogrel; contraindicated in prior stroke/TIA; increased bleeding risk. Rarely used in PAD, mainly ACS"
      },
      {
        "term": "Vorapaxar",
        "description": "Protease-activated receptor-1 (PAR-1) antagonist; approved for PAD; added to standard antiplatelet therapy reduces MACE but increases bleeding; contraindicated in prior stroke"
      },
      {
        "term": "Cilostazol",
        "description": "Phosphodiesterase-3 inhibitor with antiplatelet and vasodilator effects; improves claudication distance; contraindicated in heart failure. Not a direct antiplatelet but often used in PAD"
      },
      {
        "term": "PAD Recommendations",
        "description": "Single antiplatelet (aspirin or clopidogrel) recommended for symptomatic PAD; monotherapy preferred over DAPT for claudication; DAPT after peripheral intervention for 1-6 months"
      },
      {
        "term": "Rivaroxaban 2.5mg + Aspirin (COMPASS)",
        "description": "Low-dose rivaroxaban (2.5mg BID) + aspirin reduces MACE and MALE in stable CAD/PAD but increases bleeding; approved for vascular risk reduction"
      },
      {
        "term": "Perioperative Management",
        "description": "Continue aspirin for most vascular procedures; hold clopidogrel 5-7 days for open surgery; balance thrombotic risk vs bleeding for individual procedures"
      },
      {
        "term": "Aspirin Resistance",
        "description": "Laboratory or clinical failure of aspirin; may reflect noncompliance, drug interactions (NSAIDs), or pharmacogenomics; clinical significance debated"
      }
    ],
    "clinical_features": {
      "snomed_codes": ["372756006", "108972005"],
      "icd_10_codes": ["Z79.82"],
      "indications": ["PAD", "CAD", "Cerebrovascular disease", "Post-stent", "Secondary prevention"]
    },
    "relationships": {
      "skos:broader": ["medicine:pharmacology:cardiovascular"],
      "skos:related": [
        "medicine:vascular:pathology:pad:pad-008",
        "medicine:vascular:pharmacology:anticoagulation",
        "medicine:cardiology:stent-management"
      ],
      "skos:narrower": []
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Understand mechanisms of major antiplatelet agents",
      "Select appropriate antiplatelet regimen for PAD",
      "Know duration of DAPT after peripheral intervention",
      "Recognize contraindications and bleeding risks"
    ],
    "clinical_pearls": [
      "Aspirin or clopidogrel monotherapy for symptomatic PAD",
      "Clopidogrel is the alternative if aspirin intolerant",
      "DAPT 1-6 months after peripheral stent placement",
      "Cilostazol improves claudication but contraindicated in CHF",
      "Continue aspirin for most vascular surgeries",
      "Rivaroxaban 2.5mg BID + aspirin = COMPASS regimen for high-risk PAD"
    ],
    "common_mistakes": [
      "Using DAPT long-term for claudication (bleeding risk > benefit)",
      "Prescribing cilostazol to heart failure patients",
      "Holding aspirin for vascular surgery (usually continue)",
      "Not recognizing drug interactions (PPIs with clopidogrel - controversial)",
      "Using prasugrel in patients with prior stroke"
    ]
  }
}
